LOS ANGELES, Nov 3 (Reuters) - Eastbourne Capital, which owned a 12.5-percent stake in Amylin Pharmaceuticals Inc as of late August, said on Monday it intends to hold discussions on ways to improve shareholder value, including the possible sale of the biotechnology company.
